---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-040152"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:19:16.884572+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics reports 2022 operating loss of $17.9M; cash runway into Q2 2023

## Summary
- Cash at Dec 31, 2022: $5.0M, down from $20.8M at Dec 31, 2021.
- Operating loss of $17.9M in 2022 vs $6.8M in 2021; R&D expense $10.5M (up from $2.8M).
- Cash of $5.0M plus $1.3M from Feb 2023 offering and $871k SBIR expected to fund into but not through Q2 2023.
- FDA authorized Phase 0 FIH trial for lead candidate TTX-MC138 in advanced solid tumors.
- Strategic alliance with MD Anderson and Orphan Drug Designation for TTX-siPDL1 in pancreatic cancer.

## SEC filing metadata
- accession: 0001104659-23-040152
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923040152/0001104659-23-040152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923040152/tm2310837d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-040152
- JSON: https://secwatch.observer/filing/0001104659-23-040152.json
- Plain text: https://secwatch.observer/filing/0001104659-23-040152.txt

## Key facts
- Earnings Releases
  Transcode Therapeutics, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: TransCode Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923040152/0001104659-23-040152-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.